Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Immix Biopharma in a research report issued to clients and investors on Wednesday, June 4th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.14) per share for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Immix Biopharma's current full-year earnings is ($0.87) per share. HC Wainwright also issued estimates for Immix Biopharma's Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.65) EPS.
Immix Biopharma Stock Performance
NASDAQ IMMX traded up $0.13 during trading on Thursday, hitting $2.19. The stock had a trading volume of 293,858 shares, compared to its average volume of 154,657. Immix Biopharma has a 12 month low of $1.26 and a 12 month high of $3.00. The company's 50-day moving average price is $1.88 and its two-hundred day moving average price is $1.94. The company has a market capitalization of $61.05 million, a PE ratio of -2.58 and a beta of 0.31.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09.
Institutional Investors Weigh In On Immix Biopharma
An institutional investor recently bought a new position in Immix Biopharma stock. SBI Securities Co. Ltd. bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned approximately 0.06% of Immix Biopharma at the end of the most recent quarter. Institutional investors own 11.26% of the company's stock.
Immix Biopharma Company Profile
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Recommended Stories
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
